Portfolio


PamBio

Innovating in therapy for acute bleeding conditions  

 

PamBio - The Company

PamBio is an innovative biotechnology company developing drug therapy for Hemorrhagic stroke (intracranial bleeding, ICH) and other acute bleeding conditions.

PamBio is an NGT3 VC portfolio company, established on 2014

The Team

  • Prof. Abd Al-Roof Higazi, MD – Inventor & CSO
  • Amos Ofer, PhD, MBA – CEO
  • Nuha Higazi, PhD – Co-inventor & CTO, R&D
  • Isabelle Dai, M.Sc – Biologist - R&D
  • Marian Gorecki, PhD – Director
  • Zohar Gendler, CEO-NGT3 VC – Director
  • Paul Waymack, MD, DSc – Director
  • Avri Havron , PhD – Director
  • Saul Mashaal, PhMb, MBA - Director

Intellectual Property

  • "tPA Mutant in the Treatment of Acute Brain Injury and Neurodegenerative Disorders"- Inventors: Higazi Abd, Higazi Nuha.
  • "Plasminogen Activator Mutants as Anti-Fibrinolytic Agents" Inventors: Higazi Abd, Higazi Nuha.

The Market & Need 

Hemorrhagic stroke (intracranial bleeding, ICH) occurs mostly when small arteries in the brain rupture and bleed into the brain tissue. The more common form of stroke – ischemic stroke occurs when a blood clot disrupts the supply of blood (oxygen and nutrients) to the brain. Whereas ischemic stroke has a drug treatment (Alteplase, tPA) that promotes clot lysis, there is no drug treatment for ICH.

ICH accounts for 10-15% of all strokes. This translates annually to 1.5-2.25 M ICH incidence worldwide. Although less prevalent compared to ischemic stroke it is the most devastating form of stroke. Death rates after an ICH are 31% at 7 days and 59% at one year. Many of the survivors are left disabled. The financial annual burden of ICH in the US and the EU is estimated at US$ 43.5 B.

The Product

PamBio’s solution for ICH drug treatment is a counter intuitive one. Its drug product in development is an inactive recombinant mutant-tPA protein. Its S481A amino-acid substitution renders the protein catalytically inactive but maintains it structure and ability to interact with major components of the fibrinolytic pathway. In essence the mutant-tPA drug molecule is a competitive inhibitor to the native-tPA.

This therapeutic biomolecule has a dual, antifibrinolytic and neuroprotective effect:

  1. It is the only known antifibrinolytic drug that blocks both tPA and uPA fibrinolysis enzymes’ activity, enabling treatment in a time window beyond 3 hours.
  2. It limits tPA and glutamate mediated neurotoxicity, by blocking the binding of the neurotoxic tPA to NMDA receptors, thus providing neuroprotection.

PamBio’s mutant-tPA drug benefits include:

  • Stabilizing blood clots (in contrast to creating blood clots) and preventing bleeding
  • Increasing anti-bleeding treatment time-window beyond 3 hours
  • Minimizing blood toxicity in the brain
  • Preventing NMDA-receptor-mediated excitotoxic neuronal death
  • High degree of similarity to the tPA human protein that minimizes potential immunogenicity and organ/tissue toxicity
  • High target specificity for reduced side effects
  • High affinity binding to targets to minimize dose
  • Unique and safe mechanism of action
  • Short half-life
  • Native-tPA as antidote and mutant-tPA as antidote to the native-tPA

POC studies have shown that PamBio’s biomolecule reduce bleeding in mice brains post Traumatic Brain Injury (TBI, figure 1), with good neurological outcome (figure 2); that piglets treated with the drug post Fluid Percussion (FPI) Injury suffered less neurodegeneration; and that the drug is effective in preventing general and systemic bleeding, reducing by half both bleeding time in mice (tail bleeding) and bleeding volume in rats (liver resection).

Figure 1. Mutant-tPA prevents ICH in mice, post closed head injury (CHI). Adopted from Higazi et. al., Blood, 2015.

Figure 2. Mutant-tPA attenuates neurologic deterioration in mice, post CHI. Adopted from Higazi et. al., Blood, 2015.

 

Upcoming Milestones

Pam-Bio has finished its proof-of-concept studies and its cell line development. Its product is currently under process development – for the production of the mutant-tPA drug product. It is expected that safety studies will be conducted on the second half of 2018 and that (phase I) clinical trials will begin during 2019

Contact Informations

Amos Ofer, PhD, MBA 
CEO – PamBio Ltd. NGT3 VC Technological Incubator 
P.O. Box 1252, Nazareth Illit 17111, Israel

Cellular: +972-52-701-6050 
Work: +972-4-6098600 
Fax: +972-4-6564129 
Email: Amos@pambio.co.il


Investors - Contact Us

Entrepreneurs - Contact Us